How can micelle systems be rebuilt by a heating process? by da Silva-Filho, Miguel Adelino et al.
© 2012 Silva-Filho et al, publisher and licensee Dove Medical Press Ltd.   This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of Nanomedicine 2012:7 141–150
International Journal of Nanomedicine Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
141
OrIgINAL reSeArch
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/IJN.S25761
how can micelle systems be rebuilt by a heating 
process?
Miguel Adelino da Silva-
Filho1
Scheyla Daniela Vieira da 
Silva Siqueira1
Larissa Bandeira Freire1
Ivonete Batista de Araújo2
Káttya gyselle de holanda 
e Silva2
Aldo da cunha Medeiros3
Irami Araújo-Filho3
Anselmo gomes de 
Oliveira4
eryvaldo Sócrates Tabosa 
do egito2
1Dispersed Systems Laboratory, 
Federal University of rio grande do 
Norte (UFrN), Natal, rio grande 
do Norte, Brazil; 2Department of 
Pharmacy, UFrN, Natal, rio grande 
do Norte, Brazil; 3Department 
of experimental Surgery, UFrN, 
Natal, rio grande do Norte, Brazil; 
4Department of Drugs and Medicines, 
college of Pharmaceutical Sciences 
(UNeSP), Araraquara, São Paulo, Brazil
correspondence: eryvaldo Sócrates 
Tabosa do egito  
Laboratório de Sistemas Dispersos, 
rua Praia de Areia Branca, 8948  
Natal – rN – Brazil ceP: 59094-450 
Tel +55 84 9431 8816 
Fax +55 84 3342 9817 
email socrates@ufrnet.br
Abstract: The aim of this work was to evaluate how an aqueous micellar system   containing 
Amphotericin B (AmB) and sodium deoxycholate (DOC) can be rebuilt after heating 
treatment. Also, a review of the literature on the physicochemical and biological   properties of 
this new system was conducted. Heated (AmB-DOC-H) and unheated (AmB-DOC) micelles 
were then diluted at four different concentrations (50 mg . L −1, 5 mg . L −1, 0.5 mg . L −1, and 
0.05 mg . L −1) to   perform physicochemical studies and a pharmacotoxicity assay, in which two 
cell models were used for the in vitro experiments: red blood cells (RBC) from human donors 
and   Candida parapsilosis (Cp). While potassium (K+) and hemoglobin leakage from RBC 
were the parameters used to evaluate acute and chronic toxicity, respectively, the efficacy of 
AmB-DOC and AmB-DOC-H were assessed by K+ leakage and cell survival rate from Cp. 
The spectral study revealed a slight change in the AmB-DOC aggregate peak from 327 nm 
to 323 nm, which is the peak for AmB-DOC-H. Although AmB-DOC and AmB-DOC-H 
exhibited different behavior for hemoglobin leakage, AmB-DOC produced higher leakage than 
AmB-DOC-H at high concentrations (from 5 mg . L −1). For K+ leakage, both AmB-DOC and 
AmB-DOC-H showed a similar profile for both cell models, RBC and Cp (P , 0.05). AmB-
DOC-H and AmB-DOC also revealed a similar profile of activity against Cp with an equivalent 
survival rate. In short, AmB-DOC-H showed much less toxicity than AmB-DOC, but remained 
as active as AmB-DOC against fungal cells. The results highlight the importance of this new 
procedure as a simple, inexpensive, and safe way to produce a new kind of micelle system for 
the treatment of systemic fungal infections.
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Introduction
Amphotericin B (AmB) is a water-insoluble compound widely used to effectively 
treat systemic fungal infections.1 However, its utilization as an antifungal agent has 
been limited by high acute and chronic toxicity, characterized by chills, fever, nausea, 
vomiting, and nephrotoxicity.2–4
Due to the amphiphilic nature of the molecule and its poor solubility in water, 
AmB is able to self-associate in aqueous media and form supramolecular aggregates. 
However, in aqueous media, monomers and soluble and insoluble aggregates of AmB 
coexist, the latter being responsible for the toxic effects.5–8 When AmB in solution is 
below the minimal concentration for self-association, toxicity against fungi is still 
observed, while the human toxic effect decreases.2,3
In the current model of AmB selective toxicity, soluble monomeric AmB is able to 
form ion channels in ergosterol-rich fungal membranes, but a soluble self-associated International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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oligomer damages sterol-free and cholesterol-containing 
membranes.9,10 Also, the oligomers seem to be susceptible to 
oxidation, which may enhance their toxicity.11 Therefore, the 
way in which AmB is cleared from the body plays an impor-
tant role in its toxicity and activity. The widely-accepted 
mechanism of action of AmB described above is true for 
micelle systems; the AmB molecules bind to a surfactant with 
a high degree of freedom and can easily leave the surfactant 
molecule and self-associate.
The micellar deoxycholate system of AmB (AmB-DOC), 
a well-known commercial antifungal product (Fungizon®), 
has been used in clinical practice for over 45 years for 
the treatment of several systemic fungal infections.2,12 
Unfortunately, AmB-DOC shows a concentration-dependent 
profile of toxicity and its selectivity depends on its aggregation 
state. Clinically, nephrotoxicity is frequently observed.13
In an attempt to reduce the AmB-DOC toxicity, some 
lipid formulations such as liposomes and other AmB lipid-
associated forms were developed.14–18 These systems are 
able to immobilize the AmB monomers, preventing self-
aggregation. They slowly release monomers to the media, 
and, therefore, are active only against fungal cells. Although 
these formulations exhibit a far superior therapeutic index 
compared to AmB-DOC, they are costly and their clinical 
use is inaccessible for many countries where fungal-related 
diseases are rampant. In fact, only AmB-DOC is widely used 
in some developing countries, and after the 1990s, when 
  Fungizon® was no longer patent-protected, this product 
started to be manufactured for several brands as a generic 
product.
The literature indicates that, when subjected to controlled 
heat, AmB-DOC forms a new type of aggregate, which is less 
susceptible to oxidative degradation and less selective for the 
cholesterol in the mammalian cell membrane, thus making it 
less toxic.19–25 The heating of AmB-DOC solutions generates 
“super-aggregates,” in which the toxicity is significantly 
reduced while keeping their antifungal activity. However, 
a recent study conducted in our research group revealed 
that AmB micellar systems made by different companies 
present different profiles of activity and toxicity, probably 
due to the variation in the formation of the structure of the 
drug-surfactant micelle system as a result of changes in the 
manufacturing process or because of the quality of the raw 
materials used (our unpublished results).
The aim of this work was to evaluate the relationship 
between controlled heat treatment, the absorption spectra, 
and the pharmacotoxicity of a Brazilian brand of AmB-DOC 
in aqueous micellar solutions before and after heat treatment 
(AmB-DOC-H). In this way, a new process to rebuild a 
  pre-formed micelle system can be achieved.
Materials and methods
Preparation of the AmB-DOc  
and AmB-DOc-h samples
The stock solution of AmB-DOC (Cristália, Itapira, Brazil) 
at 5 × 10−3 M (5,000 mg . L−1) was prepared by adding 10 mL 
of water for injection into the vial and submitting it to vor-
tex shaking until complete dissolution of the lyophilized 
powder. Each vial of AmB-DOC contained 50 mg of AmB, 
approximately 41 mg of sodium deoxycholate, and phosphate 
buffer, pH 7.4.
Samples of AmB-DOC were prepared with different 
concentrations by successive dilutions 1:10 of AmB-DOC 
stock solution in order to obtain the concentrations of 
5 × 10−5 M (50 mg . L−1), 5 × 10−6 M (5 mg . L−1), 5 × 10−7 M 
(0.5 mg . L−1), and 5 × 10−8 M (0.05 mg . L−1). The heated AmB 
(AmB-DOC-H) was prepared by treatment with controlled 
heat of the AmB-DOC stock solution at 70°C for 20 minutes 
in a thermostatic bath without stirring. The temperature and 
the time exposition of the bath were checked by a built-in 
thermometer (Incoterm, Brazil) and chronometer (Model 
Labor, Hanhart, Germany), respectively. Then, following 
the same procedure as that for AmB-DOC, dilutions 
were prepared to perform a similar study of concentration 
samples.
Spectral study
Scanning spectra of both AmB-DOC and AmB-DOC-H at 
the four previously mentioned concentrations were taken by 
using a UV-VIS Spectrophotometer (Biochrom Libra S32, 
Cambridge, UK). The optical path of the quartz cuvettes used 
was 0.1 cm for the concentration of 5 × 10−5 M (50 mg . L−1); 
a 1 cm path for 5 × 10−6 M (5 mg . L−1), and a 10 cm path for 
the concentrations of 5 × 10−7 M (0.5 mg . L−1) and 5 × 10−8 M 
(0.05 mg . L−1). These paths were chosen to obtain spectra 
with absorbance values less than 0.8. Their molar extinction 
coefficients (ε) were calculated using the Beer–Lambert 
equation. All spectra were recorded at 25°C ± 0.1°C with a 
300–450 nm range.6
Preparation of red blood cell (rBc) 
suspension
This study was previously approved by the Ethical Research 
Committee of the Federal University of Rio Grande do Norte, 
protocol number 002/2009. In order to minimize sources of 
variability, one healthy female adult donor, who gave her writ-International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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ten informed consent before participating in the study, pro-
vided all normal human RBCs for the in vitro experiments. 
Five milliliters of venous blood was collected in sterile 
EDTA (1 mg/mL, ethylene-diamine-tetraacetate at 10% 
(w/v), Labtest, Lagoa Santa, Brazil) syringes and promptly 
centrifuged (Refrigerated centrifuge, ALC, Model PK121R, 
Milan, Italy) in tubes at 1,100 g for 10 minutes at 4°C. 
Plasma was carefully aspirated and the exposed buffy coat 
was removed and discarded. The RBCs were washed three 
times by centrifugation (1,100 g for 5 minutes at 4°C) and 
suspended in 5 volumes of normal saline [NaCl at 0.9% (w/v), 
B. Braun, São Paulo, Brazil]. They were then resuspended in 
4 mL of saline, counted in a Neubauer™ chamber (Splabor, 
São Paulo, Brazil), and resuspended again until the desired 
concentration (5 × 107 cells . mL−1) was achieved. The cells 
were used on the day of collection.17
Preparation of Candida parapsilosis 
suspension
A strain of Candida parapsilosis (Cp) ATCC (22019) was 
maintained on Sabouraud- Dextrose-Chloramphenicol agar 
(SDC, MicroMed, São Paulo, Brazil) at room temperature 
and passaged monthly. Before experiments, an inoculum 
from the culture was transferred to a SDC agar scope and 
incubated at 37°C for 16–18 hours. The fungal cells were 
then washed three times with normal saline, resuspended, 
counted in the central reticule of a Neubauer™ chamber, and 
resuspended again to obtain the desired cell concentration 
(5 × 107 cfu . mL−1).17
evaluation of the AmB-DOc  
and AmB-DOc-h toxicity
Because the AmB molecule binds to human cholesterol of 
the plasmatic membranes and also to ergosterol in fungal 
  membranes forming hydrophilic pores1, analysis of the 
  toxicity and efficacy of the AmB-DOC and AmB-DOC-H 
formulations was performed using two cell models, RBCs 
and Cp. The potassium ions (K+) inside the cells can be 
released by any disturbance in the cell membrane due to the 
pore formation process. In RBCs the generated pore enables 
the output of K+, but not the release of hemoglobin, which 
occurs only after the total destruction of the membrane 
barrier. The phenomenon of K+ release from model cells 
has been referred to as a chronic toxicity by some authors.6,17 
On the other hand, a strong toxicity level, which induces 
hemoglobin leakage, for RBCs, or cell death for Cp, has 
been classified as acute toxicity.6,17
Four milliliter samples of RBCs (5 × 107 cells . mL−1) 
were incubated for 1 hour at 37°C with the vehicle 
control or with different concentrations (50, 5, 0.5, and 
0.05 mg . L−1) of both AmB-DOC and AmB-DOC-H. The 
RBCs were then centrifuged for 5 minutes at 1,100 g and 
washed three times with normal saline. The pellet of RBC 
was lysed by adding 4 mL of distilled water and then 
stirred and centrifuged (1,100 g for 10 minutes) in order 
to remove membranes. The K+ content of the supernatant 
was determined using a Flame Photometer 7000 (910M 
Analyser, São Paulo, Brazil) calibrated with K+ reference at 
5 mEq . L−1. Hemoglobin was estimated from its absorption 
at 540 nm recorded on a UV-VIS Spectrophotometer 
(Biochrom Libra S32). The total K+ and hemoglobin 
content was measured for the control RBC tubes. Release 
was calculated as the difference between control and treated 
cells and expressed as a percentage of the total hemoglobin 
or K+ content. At least three different experiments were 
performed with each formulation and each experimental 
point was performed in triplicate.26
evaluation of the AmB-DOc  
and AmB-DOC-H efficacy
Two milliliter samples of fungal suspension containing 
5 × 107 cfu . mL −1 were incubated for 1 hour at 37°C with 
both AmB-DOC and AmB-DOC-H at the concentrations 
of 50, 5, 0.5, and 0.05 mg . L−1. Cells were centrifuged for 
10 minutes at 2,200 g and washed three times in normal 
saline, and 2 mL of purified water was added to the pellet 
of fungal cells. An aliquot of this pellet was lysed by 
heating for 5 minutes at 100°C and centrifuged to remove 
membranes, and free K+ was measured. The K+ leakage 
was calculated similarly to the calculation of the RBCs. For 
the cell viability evaluation, 100 µL aliquots of appropriate 
dilution of the fungal pellet were seeded, in duplicate, onto 
agar plates and incubated at 37°C. The number of colony-
forming units (CFU) was counted at 24 and 48 hours and 
expressed as a percentage of those obtained from a control 
inoculum incubated without AmB-DOC or AmB-DOC-H. 
Three different experiments were performed with each 
formulation and each experimental point was performed 
in duplicate.26
Statistical analyses
The statistical results were performed with ANOVA and t test 
to analyze the variation response in the same group and in 
different groups, respectively, using Prim 4 for   Windows 4.02 
(GraphPad Software, San Diego, CA).International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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Results
Aggregation state behavior of AmB-DOc 
and AmB-DOc-h
The AmB-DOC-H showed spectra similar to that of AmB-
DOC, which were concentration-dependent (Figures 1 and 2). 
At a low concentration, such as 5.10−8 M, the AmB presented 
a spectrum with three well-defined absorption bands, with 
λmax at 363, 385, and 408 nm, and a shoulder around 347 nm, 
which is similar to that obtained with organic solvents such 
as methanol, for the monomeric AmB. However, by increas-
ing the concentration of AmB, a new band appeared at λmax 
327 nm at the expense of the bands recorded in the longer 
wavelengths (363, 385, and 408 nm), especially the one 
characteristic of the monomeric AmB species at 408 nm, 
which is responsible for the biological activity against fungal 
cells 10. The band at 327 nm was reported in the literature as 
indicative of the presence of self-associated species of AmB. 
This band was also sensitive to AmB concentration, being 
very well defined at high concentrations as in the range of 
10 × 10−7 to 10−5 M.10
Concerning the AmB-DOC-H spectra, the band at 327 nm 
was slightly blue-shifted to 323 nm after heating. Several 
authors have stated that this band is characteristic of the 
formation of AmB super-aggregates.20 It is important to note 
that the variation in the molar extinction coefficient of AmB 
at λmax 323 nm and the peaks at 363, 385, and 408 nm are 
related to variation in the equilibrium between the monomeric 
and aggregated species of AmB, which displays an isosbestic 
point at 347 nm. See scheme.
  AmBA mB m
K
sa →  ←    (scheme 1)
where the underlined letters m and sa refer to the   monomeric 
and self-associated AmB, respectively, while K is the 
  equilibrium constant between the AmB species.
This equilibrium shows that at low concentrations 
the monomeric species of AmBm prevails, but when the 
concentration is increased the equilibrium is shifted favoring 
the predominance of the self-aggregated AmBsa.
The most important difference among the AmB-DOC 
and AmB-DOC-H spectra occurred at the concentration 
of 5 × 10−7 M, in which the band at 323 nm presented a 
higher molar extinction coefficient (ε = 71,000) compared 
to the one assigned for AmB-DOC (ε = 48,666). It should 
be emphasized that the spectra at 5 × 10−8 M were given 
to illustrate the tendency of concentration dependence. 
In fact, they should not be considered on a quantitative basis 
because of the weakness of the signals at the low wavelength 
region (maximum absorbance at 408 nm was 0.071 for 
AmB-DOC).
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Figure 1 concentration-induced changes in the AmB-DOc spectra at 25°c at 5 × 10−5 M.
Abbreviation: AmB-DOc, amphotericin B with sodium deoxycholate.International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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The data for Figures 1 and 2 show that the recorded 
spectral differences can be attributed to the different 
interactions of AmB with the surfactant aggregates provoked 
by controlled heating, and such changes remained over the 
whole range of concentrations. Therefore, the heated micelle 
process was able to produce AmB super-aggregated micelle 
systems that remained stable after the dilution process. Also, 
the physicochemical stability of such super-aggregated forms 
was demonstrated by the absence of changes on the spectra 
measured on different days over three months (results not 
shown).
Three decades ago, Ernst et al28 showed the thermally 
induced increase in aggregate size of Fungizon® aqueous 
solution at 10−5 M. This phenomenon was more evident at 
60°C and increased rapidly at higher temperatures. In an 
aqueous solution at 70°C, the apparent mass of the aggregates 
was 500-fold larger than the one at 20°C.20 Therefore, the 
term super-aggregate used for this new species of AmB is 
completely justified.20
In vitro toxicity assay for AmB-DOc  
and AmB-DOc-h
The toxicity of both AmB-DOC and AmB-DOC-H against 
RBCs was quite interesting. For K+ leakage, both   profiles 
were identical (Figure 3). No significant K+ leakage 
was observed at 0.05 mg . L−1 (5 × 10−8 M). At higher 
concentrations, this completely changes. At 0.5 mg . L−1 
(5 × 10−7 M), both products induced strong permeability of 
the cell membrane as reflected by a K+ release of around 50% 
(59.59% ± 0.41% and 50.12% ± 0.9% for AmB-DOC and 
AmB-DOC-H, respectively). At the highest concentrations 
of 5 mg . L−1 (5 × 10−6 M) and 50 mg . L−1 (5 × 10−5 M), where 
the aggregate species of AmB predominates, both systems 
presented a total release of K+.
Both AmB-DOC and AmB-DOC-H produced no 
significant hemoglobin leakage below 0.5 mg . L−1 (Figure 4). 
While the AmB-DOC-H showed no toxic effect on the 
whole range of the tested concentrations (0.05 to 50 mg . L−1, 
P , 0.001), the AmB-DOC revealed a sharp increase in the 
toxicity from 0.5 mg . L−1, reaching to fully lysed cells from 
5 mg . L−1 with total hemoglobin leakage to external media.
In vitro activity assay for AmB-DOc  
and AmB-DOc-h
The in vitro activity against Cp showed that both AmB-
DOC and AmB-DOC-H were very effective (Figure 5) and 
that the profile of K+ release was quite similar (Figure 3). 
In fact, a significant K+ leakage was found at the lowest 
concentration (0.05 mg . L−1), reaching around 85% at the 
highest concentration. In this assay AmB-DOC-H was 
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Figure 2 concentration-induced changes in the AmB-DOc-h spectra at 25°c at 5 × 10−5 M.
Abbreviation: AmB-DOc, amphotericin B with sodium deoxycholate.International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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slightly more active than AmB-DOC over the whole range 
of concentration. For example, at 5 mg . L−1 AmB-DOC-H 
presented a K+ release of 85.92% ± 0.85% while AmB-DOC 
showed a release of 79.75% ± 1.96%. At 50 mg . L−1 these 
values were 88.38 ± 0.70% and 83.98 ± 3.86%, respectively. 
However, such values were not statistically significant.
These data are in agreement with the results of the 
cell survival rate, which indicated for both AmB_DOC 
and AmB-DOC-H a significant decrease in the rate of 
survival cell at concentrations up to 0.5 mg . L−1. At this 
concentration range, the AmB-DOC-H showed higher 
antifungal activity than the unheated AmB. For example, 
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Figure 3 In vitro release of potassium from human rBcs and Candida parapsilosis induced by AmB-DOc and AmB-DOc-h.
Note: Each point on the figure is the mean (±SD) of three determinations.
Abbreviations: AmB-DOc, amphotericin B with sodium deoxycholate; AmB-DOc-h, amphotericin B with sodium deoxycholate, heated; rBc, red blood cells.
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Figure 4 In vitro release of hemoglobin from human rBcs induced by AmB-DOc and AmB-DOc-h.
Notes: Each point on the figure is the mean (±SD) of three determinations. *Significant difference between both products (P , 0.001).
Abbreviations: AmB-DOc, amphotericin B with sodium deoxycholate; AmB-DOc-h, amphotericin B with sodium deoxycholate, heated; rBc, red blood cells.International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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at the concentration of 0.05 mg . L−1 AmB-DOC-H was able 
to kill 53.72% ± 5.17% whereas AmB-DOC killed only 
32.31% ± 1.40%. Considering the standard deviation, in the 
range of concentrations from 0.5 mg . L−1 to 50 mg . L−1, the 
CFU survival rate profile was similar for both preparations. 
Finally, at 50 mg . L−1 both products were able to kill the 
totality of the fungal cells.
Discussion
Micelle systems have been used as nanotechnologic carriers 
for more than 60 years.2 Particularly for AmB, this system 
has been used since 1957 when Bartner et al studied the 
incorporation of AmB molecules into a micellar sodium 
deoxycholate (DOC), in a molar ratio of approximately 
1:2 AmB:DOC, respectively.27
The idea that a micellar complex could change its 
physicochemical property by heating remained completely 
undiscovered since the first works of Ernst et al.28 Almost 
twenty years later, Gaboriau et al20 produced a major study 
about this phenomenon by discovering the super-aggregated 
form of AmB. This new AmB species not only presents an 
important change in the absorption and circular dichroism 
spectra of AmB, which is related to its physicochemical 
state, but also reveals a biological difference when compared 
to the unheated micelle.21–25 Therefore, it can be estimated 
that the industrial production of a micellar system could be 
strongly influenced by the manufacturing process, which 
can modify the surfactant-molecule binding and generate 
different physicochemical forms.
The results of this study show that, unlike the unheated 
form, the Brazilian micelle system presents a physicochemical 
profile quite similar to the European one when heated at 70°C 
for 20 minutes, generating a superaggregated spectroscopic 
species, which was characterized by a band at 323 nm on its 
spectrum. Because this band appeared at the expense of the 
ones at 327 and 408 nm, the presence of the superaggregated 
form can be suggested to be a result of the condensation 
of the aggregated and monomer species of the AmB. This 
explanation is in complete agreement with the study of 
Gaboriau et al using a European AmB-DOC (Fungizon®).20 
Unlike the AmB aggregate species, the dissociation of this 
super-aggregated form into monomers occurs at lower AmB 
concentrations.29 Therefore, it can be inferred that the AmB 
super-aggregated species may be considered a reservoir of 
monomeric AmB species that releases only a limited amount 
of monomeric AmB in the aqueous media. As a consequence, 
the concentration of monomeric AmB might be below its 
critical aggregation concentration, which is around 10−6 M; 
thus, the drug can remain in its monomeric form. This form 
would be able to bind to the ergosterol of fungal cells, but 
unable to bind to the cholesterol of the RBCs.10
In fact, the variation of patterns of activity against 
ergosterol-containing fungal cells with respect to toxicity 
against cholesterol-containing mammalian cells and its 
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Figure 5 In vitro antifungal activity of AmB-DOc and AmB-DOc-h on C. parapsilosis.
Notes: Each point on the figure is the mean (±SD) of three determinations. *Significant difference between both products (P , 0.001).
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dependence on the AmB molecular presentation has been 
reported by several research groups.1,6,26,30 It is well-estab-
lished that the monomeric species of AmB is less effec-
tive than the aggregated form in inducing permeability of 
membranes containing cholesterol, leading to potassium 
leakage.31 The AmB aggregated form was shown to trigger 
permeability changes in RBC membranes and to induce 
cytotoxic events.10 Such correlation was also maintained in 
several in vivo studies.32–34
The present study reveals that the equilibrium between 
the different species of AmB in aqueous media may change 
and, therefore, its overall activity or toxicity could be 
changed. The spectral evaluation of both AmB-DOC and 
AmB-DOC-H clearly demonstrates that the behavior of AmB 
molecules was modified. For example, the concentration 
dependence, characteristic of AmB-DOC, disappeared at 
the concentration of 5 × 10−7 M. In fact, at this concentration 
the AmB super-aggregated band, located at 323 nm, was 
maintained, whereas the proportion of the monomeric 
form remained low (Figure 2). This suggests that the AmB 
molecules were strongly bound to the surfactant molecule and 
the micelle system had a greater strength than the unheated 
ones.26 Only at the lowest concentration (5 × 10−8 M) did both 
products present a similar spectrum in which the monomeric 
band had the same shape and similar intensity, reflected by 
almost the same value of ε.
The reservoir model hypothesis suggested for the super-
aggregated form of AmB was demonstrated by the in vitro 
studies. When the target cells were human RBCs, AmB-
DOC-H was unable to induce hemoglobin leakage over the 
whole range of doses tested (Figure 4). This demonstrated 
that the existing aggregated form at 5 × 10−6 M and 5 × 10−5 
M was completely different from the AmB-DOC-H product. 
On the other hand, the activity of both products was quite 
similar when the cell model was a membrane containing 
ergosterol, as in the Candida parapisilosis.
The statistical comparison among the different concen-
trations of AmB for both AmB-DOC and AmB-DOC-H 
  products by the ANOVA test was significant (P , 0.001), 
which confirms that the dilution process induced a decrease 
in the pattern of activity for all samples. Additionally, 
  Student’s t-test showed that the toxicity assay against RBCs, 
  represented by the release of K+ and hemoglobin, was 
  significantly different from that for AmB-DOC-H, which 
was much smaller than AmB-DOC (P , 0.05).
The probable mechanism behind this pattern of activity 
could be the high chemical stability of the AmB super-
aggregates, which are less susceptible to peroxidative 
process than the aggregated form and, therefore, present 
less affinity to membranes containing cholesterol than the 
unheated preparation.8,22 Also,8,12 this protection against the 
peroxidation process allows the AmB super-aggregated form 
to act as a controlled release of the monomeric AmB species, 
which is able to maintain its antifungal activity.10 Therefore, 
as suggested in the literature, a complete resculpting of AmB 
aggregates probably occurs with the heat-inducing process, 
and this phenomenon induces changes in the AmB distribu-
tion and interaction with various serum fractions.29
A mechanistic rationale for the similar efficacy and 
lower toxicity of AmB-DOC-H, compared to AmB-DOC, 
as previously proposed, reports that AmB-DOC can be 
rapidly converted from its aggregated form to a protein-
bound monomer in the presence of human serum albumin, 
whereas AmB-DOC-H demonstrates greater stability by 
persisting as a stable inactive aggregate.12 Moreover, the 
increased therapeutic index of the AmB-DOC-H may also 
be the result of greater phagocytosis of the super-aggregates, 
owing to their larger size (600 nm), which allows them 
to be efficiently engulfed by the macrophages and to be 
transferred to the site of infection in the case of internal cell 
infections such as leishmaniosis.19 On the other hand, it was 
also shown that the cytotoxicity may be decreased due to a 
reduction of the interaction of AmB-DOC-H with the kidney 
cell membranes.35
The benefits of the pre-heating process for AmB-DOC 
(Fungizon®) were also studied in persistently leukopenic 
mice with severe invasive candidiasis, concluding that higher 
dosages of AmB-DOC-H, (3.0 versus 0.8 mg . L−1 of body 
weight), were tolerated, compared to AmB-DOC, resulting in 
significantly improved therapeutic efficacy.36 The cytotoxicity 
of AmB-DOC-H against pig kidney cells was evaluated by 
Bartlett et al, who discovered a decrease in the AmB renal 
cytotoxicity without modifying its antifungal activity.25 In the 
same way, Bau et al37 showed the benefits of the patent-free 
heated AmB product for use by public-health authorities or 
a reactive non-governmental organization for treatment of 
leishmaniasis23 and other neglected diseases.
Other important studies have been carried out with the 
AmB-DOC (Fungizon®) heated form. For example, a recent 
work evaluated the fluorescence of AmB aggregates for the 
heated and unheated form. The authors concluded that not 
only the monomer and dimer AmB states but also the aggre-
gate and super-aggregate forms present different spectra.38 
Therefore, the fluorescence technique could also be used 
to characterize the different AmB state forms. Rogers et al 
studied the cytokine and chemokine response elicited by International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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AmB-DOC-H in comparison to AmB-DOC in the human 
monocyte cell line THP-1.24 They concluded that AmB-DOC 
produced dose-dependent increases in interleukin (IL)-1β, 
IL-1α, tumor necrosis factor-α, macrophage inflammatory 
protein (MIP)-1α, and MIP-1β and that AmB-DOC-H 
induced cytokine and chemokine production at a lower level 
than those observed with the corresponding concentrations 
of AmB-DOC.24
Conclusion
Heat treatment of Fungizon® was shown to modify the 
aggregation state of the AmB desoxicholate micellar 
  system, generating an AmB super-aggregate species whose 
appearance is concomitant with the disappearance of both 
normal aggregates and monomeric AmB species.
All the results together suggest that the AmB-DOC-H, 
from a Brazilian industrial company, was less toxic than 
the unheated form (AmB-DOC) probably due to changes 
in the AmB aggregation state. It is possible to rebuild 
micelle   systems and generate new entities at a nanoscale 
level by simple heating. Therefore, we can speculate that 
this   strategy opens the way to creating nanocarriers by 
  changing the manufacturing parameters and process of 
micelle production.
In short, heat treatment of Fungizon® solutions has been 
shown to be a simple and inexpensive alternative for treating 
patients with systemic fungal infections. AmB-DOC-H 
has been demonstrated to be less toxic to mammalian cells 
while keeping its activity against fungal cells and protozoan 
microorganisms. This hypothesis is supported not only by 
the results presented here, but also by the results found in the 
literature, which were extensively discussed in this paper.
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